|
1
|
Havasi A, Cainap SS, Havasi AT and Cainap
C: Ovarian cancer-insights into platinum resistance and overcoming
it. Medicina (Kaunas). 59(544)2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lheureux S, Braunstein M and Oza AM:
Epithelial ovarian cancer: Evolution of management in the era of
precision medicine. CA Cancer J Clin. 69:280–304. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pignata S, C Cecere S, Du Bois A, Harter P
and Heitz F: Treatment of recurrent ovarian cancer. Ann Oncol. 28
(suppl_8):viii51–viii56. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yang L, Xie HJ, Li YY, Wang X, Liu XX and
Mai J: Molecular mechanisms of platinum-based chemotherapy
resistance in ovarian cancer (Review). Oncol Rep.
47(82)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Arnaoutoglou C, Dampala K, Anthoulakis C,
Papanikolaou EG, Tentas I, Dragoutsos G, Machairiotis N,
Zarogoulidis P, Ioannidis A, Matthaios D, et al: Epithelial ovarian
cancer: A five year review. Medicina (Kaunas).
59(1183)2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Song M, Cui M and Liu K: Therapeutic
strategies to overcome cisplatin resistance in ovarian cancer. Eur
J Med Chem. 232(114205)2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Goldberg JM, Piver MS, Hempling RE and
Recio FO: Paclitaxel and cisplatin combination chemotherapy in
recurrent epithelial ovarian cancer. Gynecol Oncol. 63:312–317.
1996.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ozols RF: Paclitaxel (Taxol)/carboplatin
combination chemotherapy in the treatment of advanced ovarian
cancer. Semin Oncol. 27 (3 Suppl 7):S3–S7. 2000.PubMed/NCBI
|
|
10
|
van Zyl B, Tang D and Bowden NA:
Biomarkers of platinum resistance in ovarian cancer: What can we
use to improve treatment. Endocr Relat Cancer. 25:R303–R318.
2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Loret N, Denys H, Tummers P and Berx G:
The role of epithelial-to-mesenchymal plasticity in ovarian cancer
progression and therapy resistance. Cancers (Basel).
11(838)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ahmed N, Abubaker K, Findlay J and Quinn
M: Epithelial mesenchymal transition and cancer stem cell-like
phenotypes facilitate chemoresistance in recurrent ovarian cancer.
Curr Cancer Drug Targets. 10:268–278. 2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Rosanò L, Cianfrocca R, Spinella F, Di
Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG and Bagnato
A: Acquisition of chemoresistance and EMT phenotype is linked with
activation of the endothelin A receptor pathway in ovarian
carcinoma cells. Clin Cancer Res. 17:2350–2360. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Cao L, Wan Q, Li F and Tang CE: MiR-363
inhibits cisplatin chemoresistance of epithelial ovarian cancer by
regulating snail-induced epithelial-mesenchymal transition. BMB
Rep. 51:456–461. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Liang F, Ren C, Wang J, Wang S, Yang L,
Han X, Chen Y, Tong G and Yang G: The crosstalk between STAT3 and
p53/RAS signaling controls cancer cell metastasis and cisplatin
resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT
and autophagy. Oncogenesis. 8(59)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Qiu Y, Chen Y, Zeng T, Guo W, Zhou W and
Yang X: High-mobility group box-B1 (HMGB1) mediates the
hypoxia-induced mesenchymal transition of osteoblast cells via
activating ERK/JNK signaling. Cell Biol Int. 40:1152–1161.
2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao
L, Huang J, Yu Y, Fan XG, Yan Z, et al: HMGB1 in health and
disease. Mol Aspects Med. 40:1–116. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R,
Vernon P, Cao L and Tang D: HMGB1 promotes drug resistance in
osteosarcoma. Cancer Res. 72:230–238. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zheng H, Chen JN, Yu X, Jiang P, Yuan L,
Shen HS, Zhao LH, Chen PF and Yang M: HMGB1 enhances drug
resistance and promotes in vivo tumor growth of lung cancer cells.
DNA Cell Biol. 35:622–627. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Li S and Wei Y: Association of HMGB1,
BRCA1 and P62 expression in ovarian cancer and chemotherapy
sensitivity. Oncol Lett. 15:9572–9576. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Shu W: Downregulation of high mobility
group protein box-1 resensitizes ovarian cancer cells to
carboplatin. Oncol Lett. 16:4586–4592. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Curtin JF, Liu N, Candolfi M, Xiong W,
Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, et
al: HMGB1 mediates endogenous TLR2 activation and brain tumor
regression. PLoS Med. 6(e10)2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Candolfi M, Yagiz K, Foulad D, Alzadeh GE,
Tesarfreund M, Muhammad AK, Puntel M, Kroeger KM, Liu C, Lee S, et
al: Release of HMGB1 in response to proapoptotic glioma killing
strategies: Efficacy and neurotoxicity. Clin Cancer Res.
15:4401–4414. 2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Chen Y, Cai L, Guo X, Li Z, Liao X, Zhang
X, Huang L and He J: HMGB1-activated fibroblasts promote breast
cancer cells metastasis via RAGE/aerobic glycolysis. Neoplasma.
68:71–78. 2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Li H, Li J, Zhang G, Da Q, Chen L, Yu S,
Zhou Q, Weng Z, Xin Z, Shi L, et al: HMGB1-Induced p62
overexpression promotes snail-mediated epithelial-mesenchymal
transition in glioblastoma cells via the degradation of GSK-3β.
Theranostics. 9:1909–1922. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhang Y, Ren H, Li J, Xue R, Liu H, Zhu Z,
Pan C, Lin Y, Hu A, Gou P, et al: Elevated HMGB1 expression induced
by hepatitis B virus X protein promotes epithelial-mesenchymal
transition and angiogenesis through STAT3/miR-34a/NF-κB in primary
liver cancer. Am J Cancer Res. 11:479–494. 2021.PubMed/NCBI
|
|
27
|
Chen J, Liu X, Zhang J and Zhao Y:
Targeting HMGB1 inhibits ovarian cancer growth and metastasis by
lentivirus-mediated RNA interference. J Cell Physiol.
227:3629–3638. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zheng Q, Xu Y, Lu J, Zhao J, Wei X and Liu
P: Emodin Inhibits Migration and Invasion of Human Endometrial
Stromal Cells by Facilitating the Mesenchymal-Epithelial Transition
Through Targeting ILK. Reprod Sci. 23:1526–1535. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Yeung KT and Yang J:
Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol.
11:28–39. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Mittal V: Epithelial mesenchymal
transition in tumor metastasis. Annu Rev Pathol. 13:395–412.
2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Li L, Li P, Zhang W, Zhou H, Guo E, Hu G
and Zhang L: FERMT1 contributes to the migration and invasion of
nasopharyngeal carcinoma through epithelial-mesenchymal transition
and cell cycle arrest. Cancer Cell Int. 22(70)2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Cui X, Wang Y, Lan W, Wang S, Cui Y, Zhang
X, Lin Z and Piao J: SPOCK1 promotes metastasis in pancreatic
cancer via NF-κB-dependent epithelial-mesenchymal transition by
interacting with IκB-α. Cell Oncol (Dordr). 45:69–84.
2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Liang H, Yu T, Han Y, Jiang H, Wang C, You
T, Zhao X, Shan H, Yang R, Yang L, et al: LncRNA PTAR promotes EMT
and invasion-metastasis in serous ovarian cancer by competitively
binding miR-101-3p to regulate ZEB1 expression. Mol Cancer.
17(119)2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kim LK, Park SA, Yang Y, Kim YT, Heo TH
and Kim HJ: LncRNA SRA mediates cell migration, invasion, and
progression of ovarian cancer via NOTCH signaling and
epithelial-mesenchymal transition. Biosci Rep.
41(BSR20210565)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
He H, Wang X, Chen J, Sun L, Sun H and Xie
K: High-Mobility Group Box 1 (HMGB1) promotes angiogenesis and
tumor migration by regulating hypoxia-inducible factor 1 (HIF-1α)
expression via the phosphatidylinositol 3-kinase (PI3K)/AKT
signaling pathway in breast cancer cells. Med Sci Monit.
25:2352–2360. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
van Beijnum JR, Nowak-Sliwinska P, van den
Boezem E, Hautvast P, Buurman WA and Griffioen AW: Tumor
angiogenesis is enforced by autocrine regulation of high-mobility
group box 1. Oncogene. 32:363–374. 2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Chung HW, Jang S, Kim H and Lim JB:
Combined targeting of high-mobility group box-1 and interleukin-8
to control micrometastasis potential in gastric cancer. Int J
Cancer. 137:1598–1609. 2015.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Liu PL, Liu WL, Chang JM, Chen YH, Liu YP,
Kuo HF, Hsieh CC, Ding YS, Chen WW and Chong IW: MicroRNA-200c
inhibits epithelial-mesenchymal transition, invasion, and migration
of lung cancer by targeting HMGB1. PLoS One.
12(e0180844)2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Li Y, Tian J, Fu X, Chen Y, Zhang W, Yao H
and Hao Q: Serum high mobility group box protein 1 as a clinical
marker for ovarian cancer. Neoplasma. 61:579–584. 2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Paek J, Lee M, Nam EJ, Kim SW and Kim YT:
Clinical impact of high mobility group box 1 protein in epithelial
ovarian cancer. Arch Gynecol Obstet. 293:645–650. 2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Jiang W, Jiang P, Yang R and Liu DF:
Functional role of SIRT1-induced HMGB1 expression and acetylation
in migration, invasion and angiogenesis of ovarian cancer. Eur Rev
Med Pharmacol Sci. 22:4431–4439. 2018.PubMed/NCBI View Article : Google Scholar
|
